Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Read more about PIQRAY® (alpelisib), always given in combination with fulvestrant.

PIQRAY® (alpelisib) is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.

 

PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Reference

  1. PIQRAY® (alpelisib) Summary of Product Characteristics. Novartis Pharma; 2020.
Rate this content: 
No votes yet
HCP20-C003 September 2020.
×

Ask Speakers

×

Medical Information Request

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects. See https://yellowcard.mhra.gov.uk/ for how to report side effects.

 

 

 

 

 

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com